Sumamed, 500 mg 3 pcs

Pharmacotherapeutic group: antibiotic azalide

Code ATX: J01FA10

Pharmacological properties

Pharmacodynamics. Azithromycin is a bacteriostatic broad-spectrum antibiotic of the macrolide-azalid group. It has a broad spectrum of antimicrobial action. The mechanism of action of azithromycin is associated with inhibition of microbial cell protein synthesis. Binding to 50S-subunit of ribosome, it inhibits peptide translocase at the translation stage and inhibits protein synthesis, slowing down the growth and reproduction of bacteria. In high concentrations it has a bactericidal effect.

It has activity against a number of Gram-positive, Gram-negative, anaerobic, intracellular and other microorganisms.

Microorganisms can be resistant to the antibiotic from the start or they can become resistant to it.

Azithromycin sensitivity scale for microorganisms (Minimum inhibitory concentration (MIC), mg/L):

> 0.5
> 4
> 0.5

Inmostsensitive microorganisms

1. Gram-positive aerobes

Staphylococcus aureus methicillin-sensitive

Streptococcus pneumoniae penicillin-sensitive

Streptococcus pneumoniae./p>

Streptococcus pyogenes

2. Gram-negative aerobes.

Haemophilus influenzae

em>Haemophilus parainfluenzae

Legionella pneumophila<

Moraxella catarrhalis

PasteurellaPasteurella multocida

Neisseria gonorrhoeae

3. Anaerobes

Clostridium perfringens

Fusobacterium spp.

Prevotella spp.

Porphyriomonas spp.

4. Other microorganisms

Chlamydia pneumoniae

Chlamydia psittaci

Mycoplasma pneumoniae</em/em>

Mycoplasma hominis

Borrelia burgdorferi

Gram-positive aerobes

Microorganisms that can develop resistance to azithromycin

Streptococcus pneumoniae penicillin-resistant

Initially resistant microorganisms./strong>

Grampositive aerobes

Enterococcus <emfaecalis

Staphylococci (methicillin-resistant staphylococci have a very high frequency of acquired resistance to macrolides)

Gram-positive bacteria that are resistant to erythromycin.

Anaerobes

Bacteroides fragilis

Pharmacokinetics. Azithromycin is well absorbed and rapidly distributed in the body after oral administration. After a single dose of 500 mg bioavailability is 37% (first pass effect), maximum concentration (0.4 mg/l) in blood is achieved after 2-3 hours, apparent volume of distribution is 31.1 l/kg, binding to proteins is inversely proportional to the blood concentration and is 7-50%. It penetrates through cell membranes (effective in infections caused by intracellular pathogens). It is transported by phagocytes to the site of infection, where it is released in the presence of bacteria. Easily passes the histohematic barriers and enters the tissues. Concentration in tissues and cells is 10-50 times higher than in plasma, and in the focus of infection it is 24-34% higher than in healthy tissues.

Asithromycin has a very long half-life of 35-50 h. The tissue elimination half-life is much longer. The therapeutic concentration of azithromycin is maintained up to 5-7 days after the last dose. Azithromycin is mainly excreted unchanged – 50% by the intestine, 6% by the kidneys. In the liver it is demethylated, losing activity.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

Synopsis

Contraindications

Side effects

Overdose

Pregnancy use

Similarities